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Chapter I  
General Introduction 
Outline 
Immunity is a special form of self-defense found in higher animals. Errors in the 
immune system are related to a range of diseases. Accordingly, the control of such 
errors is a possible mode of therapy for diseases. In this chapter, development of cancer 
vaccines are introduced with these keywords, which are a focus on cancer, immunity, 
and drug delivery systems (DDSs). In addition, in this thesis, the outline of a CpG/SPG 
complex for novel cancer vaccination, TAT-ODN/AS-ODN/SPG of cytosol delivery 
and pH responsiveness lipid micelle for protein delivery to cytosol are explained. 
  
  9 
I-1 Cancer Therapy 
1.1 Cancer 3 
Cancer is a major public health problem in Japan and around the world. It is the 
leading cause of death in Japan and elsewhere. The number of cancer patients in Japan 
is currently 800,000 (Figure 1); this number is increasing and is expected to continue 
to do so in the future. 
1.2 Current state of cancer therapy 3 
Currently, the three major cancer therapies used in a clinical context are radiation 
therapy, surgical therapy, and chemotherapy. These therapies have shown that cancer 
is not an incurable disease and have helped those inflicted to survive longer. However, 
these approaches also have side effects, many of which have yet to be resolved. This is 
one key area of research for the improvement of cancer treatment. The development of 
a range of novel cancer therapies is also ongoing. Such therapies are being developed 
based on interdisciplinary cancer expertise and are enabling improved treatment, 
widespread prevention, and early detection as never before. These novel therapies 
include proton therapy, heavy ion radiotherapy, immunotherapy, laparoscopic surgery, 
and radiofrequency ablation. However, these are not major cancer therapies yet 
because of their need for advanced equipment and the high cost associated with this. 
Therefore, a wide range of research on novel cancer therapies is still being undertaken. 
A lot of cancer patients will be have liberty of cancer therapy options with needs, 
which are efficacy, cost, combination therapy, and etc., by this diversity cancer 
therapies.  
1.3 Cancer escapes immune surveillance 7,8 9  
Rudolf Virchow (1821–1902), known as the “Father of Pathology”, was a 19th 
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Figure. 1 A number of cancer patients in Japan in 2012 from National cancer center of Japan. 
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century German pathologist who provided the first indication of a possible link 
between immunity and cancer. Immunity is divided into two major categories: innate 
and adaptive immunity. The innate immunity is early response and induces adaptive 
immunity by antigen presenting. Then the induced adaptive immunity defenses 
strongly and memorizes immunity. The body’s defense against cancer is induced by 
the presentation of antigens and signaling from components of the innate immune 
system to the adaptive immune system. However, cancer cells are known to escape 
immune surveillance by establishing several types of immune suppression (Figure 2). 
Tumor cell-intrinsic mechanisms: avoidance of immune recognition and elimination 
・	 Defects in major histocompatibility complex (MHC) class I proteins (e.g., genetic 
loss of the MHC locus) 
・	 Epigenetic silencing of the antigen processing machinery [e.g., transporter associated 
with antigen processing (TAP)] 
・	 Loss of tumor-associated antigens (e.g., dedifferentiation of melanoma cells) 10 
・	 Expression of ligands for inhibitory receptors [e.g., programmed cell death protein 1 
ligand 1 (PDL1)] 
Tumor cell-extrinsic mechanisms: creation of an immune-suppressive microenvironment 
・	 Infiltration with suppressive cells [e.g., regulatory T cells (Tregs), macrophages, and 
myeloid-derived suppressor cells (MDSCs)] 
・	 Secretion of immune-suppressive cytokines [e.g., transforming growth factor-β 
(TGFβ), interleukin-10 (IL-10), and vascular endothelial growth factor (VEGF)] 
Immunotherapy is one novel cancer therapy that works by limiting the escape from 
immune surveillance by these above mechanisms. Breakthroughs in immunotherapy 
have been achieved via the use of checkpoint inhibitors, chimeric antigen receptor 
(CAR), T-cell therapy, and cancer vaccine (Figure 3). Remarkable progress in treating 
cancer has recently been achieved via these immunotherapies. In the near future, 
immunotherapy should become one of the major forms of cancer therapy. 
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Figure. 2 Tumor escape gives rise to alternative peptide antigens. The three phases of cancer 
immune-editing.  
Cancer describe the intricate relationship between a tumor and its infiltrating immune system, 
during which genetic instability and tumor heterogeneity increase and immune selection of tumor 
cell variants occurs. In the first phase (part a), the immune system is in control, which results in 
the elimination of tumor cells. In the second phase (part b), tumor cell variants arise that have 
increasing capacity to survive immune attack, such that in the third phase (part c), the tumor 
escapes immune control and additional tumor cell variants develop. The escape phase is 
characterized by a multitude of tumor-intrinsic mechanisms that enable the tumor to avoid 
immune recognition, as well as tumor-extrinsic mechanisms that result in active immune 
suppression in the microenvironment. During the first phase, tumor cells generally express high 
cell-surface levels of major histocompatibility complex (MHC) class I, their antigen processing 
machinery (APM) is still intact and they are easily recognized by CD8+ T cells that are specific 
for conventional tumor antigens (part d). In the later phases, tumor cells show a decrease in the 
cell-surface levels of MHC class I that is often associated with less antigen presentation owing to 
APM defects; thus, there is reduced recognition and eradication of tumor cells by CD8+ T cells 
specific for conventional tumor antigens. However, a new set of tumor antigens arises; these are 
known as T cell epitopes associated with impaired peptide processing (TEIPP) and constitute 
alternative peptides that are uniquely presented by tumors in the escape phase. The copyright is 
owned by the Nature Publishing Group, from which permission to reproduce this figure was 
obtained 5. 
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I-2 Cancer Vaccination 
1.1 Vaccines 
The work of Edward Jenner (1749–1823), the first to develop a vaccine based on 
immune mechanisms, benefited the human race tremendously. Vaccines activate 
self-defense with innate to adaptive immunity by using non-self-antigens such as 
bacteria and viruses and exhibits various functions depending on the type of antigen.  
1.2 Cancer vaccinations 1,11 
Generally, tumor antigens are classified into two categories: (1) tumor-associate 
antigens (TAAs), which are overexpressed in tumor cells compared with their level in 
normal cells; and (2) tumor-specific antigens (TSAs), which are expressed only in 
tumor cells. TSAs are much less well defined and little is known about them. One 
potential option for treating cancers is to administer an artificially designed antigen 11, 
such as a synthetic antigenic peptide or protein, for cancer vaccination. 
Although many pre-clinical and clinical trials of cancer vaccines have been undertaken 
since the mid-1990s 12,13, most of them failed to reach a level of efficacy for clinical 
application, in contrast to other cancer therapies, and for immune escape mechanisms. 
One major cause of this failure was an inability to induce significant immune responses 
because of the lack of an appropriate adjuvant and delivery carrier to a responsive 
immunocyte 14. 
1.3 Cancer adjuvants 4,15 
Adjuvants are introduced exogenous substances, when combined with an antigen, 
enhance antigenicity and elicit the desired immune response. To inhibit immune escape 
and cancer growth, it is necessary to control the immune system not only by using a 
  15 
suitable antigen for a cancer vaccine, but also by introducing an appropriate adjuvant. 
The external factors pathogen-associated molecular patterns (PAMPs) activate innate 
immunity to induce adaptive immunity through pattern recognition receptors (PRRs) 
(Figure 3). PAMPs have been developed as an adjuvant, shown to be efficacious for 
several vaccines, and entered into clinical trials (Table 1). When developing an adjuvant, 
the necessary features include a lack of side effects, efficacy, low cost, and cleary 
immunity mechanisms. 
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Figure. 3 Induction of adaptive immune responses to vaccines through PRR-mediated dendritic 
cell activation.  
Vaccines may contain pathogen-associated molecular patterns (PAMPs) or may induce the local 
release of damage-associated molecular patterns (DAMPs). These PAMPs and DAMPs are 
detected directly by pattern-recognition receptors (PRRs) expressed by dendritic cells (DCs), 
leading to DC activation, maturation and migration to the lymph nodes. Alternatively, 
PRR-mediated recognition of PAMPs and DAMPs by bystander cells may induce the release of 
tissue-derived factors, such as cytokines, that may cooperate in the activation and orientation of 
the DC response. In the lymph nodes, the activated DCs may present antigens to T cells, provide 
them with co-stimulatory signals and stimulate their differentiation by providing a favorable 
cytokine milieu. The copyright is owned by the Nature Publishing Group, from which permission 
to reproduce this figure was obtained 4. 
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Table. 1 Active immunotherapies in phase III development. The copyright is owned by the Nature 
Publishing Group, from which permission to reproduce this table was obtained 1. 
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I-3 Drug Delivery Systems and Cancer Vaccines 
1.1 Drug delivery systems 
The German Nobel laureate Paul Ehrlich (1854–1915) introduced the concept of “magic 
bullets” for efficacy drug delivery more than 100 years ago 16. This concept is first 
generation of drug delivery systems (DDSs), which have research widely at recent. 
Figure 4 shows several nanocarriers in nanotherapeutic platforms. Nanocarriers are 
excellent for drug delivery as they contribute multiple functions. The design of 
nanocarriers, including their morphology, size, and chemical surface, plays a significant 
role in their cellular uptake and targeting site (Figure 5) 6. Therefore, the functionality of 
carriers is important for efficacy. (e.g. Responsible pH and enzyme) 
For the medical application of a DDS, it is important to fulfill the criteria set by drug 
administration agencies. This refers not only to efficacy, pharmacokinetics, and safety 
profiles but also to prove clearly chemical, physical factors, and their measuring 
techniques based on materials. 
1.2 Cancer vaccinations and DDSs 5,6 
Nanocarrier design for effective cancer vaccines requires the ability to overcome 
relevant tissue barriers and efficiently deliver an antigen with an adjuvant to 
antigen-presenting cells (APCs). Then, APCs can induce cytotoxic T lymphocytes 
(CTLs) at lymph nodes by presenting the antigen to them along with co-signals. 
Recently, several groups have expanded upon the size-based targeting strategy of 
nanocarriers to also incorporate specific ligands to promote vaccine particle capture by 
specific cell types in lymph nodes. We believe that cancer vaccination with a DDS, 
which is highly efficacious and enables complete recovery from cancer, will soon 
provide a successful option for cancer therapy. 
  19   
 
 
Figure. 4 Schematic illustration of established nanotherapeutic platforms.  
Different nanomedicine products such as drug conjugates, lipid-based nanocarriers, 
polymer-based nanocarriers, inorganic nanoparticles, and viral nanoparticles are used in clinical 
cancer care. The copyright is owned by the Elsevier, from which permission to reproduce this figure 
was obtained 2.  
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Figure. 5 Nanoparticle size, shape and surface charge dictate biodistribution among the different 
organs including the lungs, liver, spleen and kidneys. (a) Spherical particles, including gold 
nanoparticles, liposomes and polymeric micelles/nanoparticles can vary in size and display disparate 
in vivo fates. Large rigid particles with diameters >2,000 nm accumulate readily within the spleen 
and liver, as well as in the capillaries of the lungs. Nanoparticles in the range of 100–200 nm have 
been shown to extravasate through vascular fenestrations of tumors (the EPR effect) and escape 
filtration by liver and spleen. As size increases beyond 150 nm, more and more nanoparticles are 
entrapped within the liver and spleen. Small-sized nanoparticles (<5 nm) are filtered out by the 
kidneys. (b) Novel ‘top-down’ and ‘bottom up’ fabrication techniques have enabled the exploration 
of different geometries of nanoparticles, including cylindrical and discoidal shapes, which have 
been shown to exhibit pronounced effects on pharmacokinetics and biodistribution. Different 
nanoparticle shapes exhibit unique flow characteristics that substantially alter circulating lifetimes, 
cell membrane interactions and macrophage uptake, which in turn affect biodistribution among the 
different organs. (c) Charge of nanoparticles stemming from distinct surface chemistries influences 
opsonization, circulation times and interaction with resident macrophages of organs comprising the 
MPS, with positively charged particles more prone to sequestration by macrophages in the lungs, 
liver and spleen. Neutral and slightly negatively charged nanoparticles have longer circulation 
lifetimes and less accumulation in the aforementioned organs of the MPS. In both b and c, the size 
of the nanoparticles is assumed to range from 20–150 nm. Individual panels represent in vivo fates 
of nanoparticles, taking into account singular design parameters of size, shape and surface charge 
independent of one another, and for this reason, respective scales vary from one panel to the next. It 
is important to note that in vivo biodistribution will undoubtedly vary based on the interplay of 
several of the above parameters. The copyright is owned by the Nature Publishing Group, from 
which permission to reproduce this figure was obtained 6.
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I-4 Sakurai’s previous technology: ODN/SPG complex 
1.1 Schizophyllan (SPG) 
Chinese herbal medicine has a long history, probably extending back to about 2500 to 
3000 years ago. Over the course of this history, some fungi were recognized as potential 
medicines to cure gynecological diseases 17. Modern chemistry subsequently revealed 
that the active ingredients of such fungi are polysaccharides belonging to the 
β-1,3-glucan family 18. Among others, schizophyllan (SPG; see Figure 6 for the 
chemical structure) 19,20 and lentinan 18 have been commercialized as medicines for 
uterine cancers in Japan. Immunological studies have shown that these glucans can 
activate natural immunity by promoting the secretion of interleukins 18. Toll-like 
receptors are known to be responsible for the recognition of β-1,3-glucans and to induce 
the up-regulation of these biological responses. The chemistry of β-1,3-glucans has a 
relatively long history, whereas the immunological and molecular biological study of 
β-1,3-glucans has just started, since the finding of Toll-like receptors. Atkins 21 and 
Sarko 22,23 showed that the simplest β-1,3-glucan, known as curdlan (Figure 5), forms a 
triple helix in nature. Norisuye et al. 24-26 carefully studied the dilute solution properties 
of SPG and clarified that it dissolves in water as a triple helix (t-SPG) and in 
dimethylsulfoxide (DMSO) as a single chain (s-SPG). Furthermore, when water is 
added to s-SPG/DMSO solution, t-SPG is regenerated from three s-SPG chains via 
hydrophobic and hydrogen bonding interactions (known as the renaturation process) 27. 
Although the renatured product is not exactly the same as the original rod-like 
molecules, the local structure was proved to restore the triple helix 27,28.
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Figure. 6 Chemical strictures of Curdlan and Schizophyllan(SPG).  
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1.2 ODN/SPG complex 
In 2000, Sakurai et al. found that SPG can form a macromolecular complex with several 
homo-phosphodiester polynucleotides, such as poly(C), poly(A), poly(U), poly(dA), 
and poly(T), when the polynucleotide is present during the renaturation process of 
single-chain SPG (s-SPG) 29-33. The novel features possessed by this complex include: 
(1) remarkable stability (large binding constant) and water solubility under 
physiological conditions, (2) the formation of a highly stoichiometric complex, with the 
stoichiometric number indicating the interaction between two s-SPG units and three 
base units (i.e., two main chain glucoses vs. one nucleotide) 29, (3) immediate 
dissociation of the complex followed by hybridization when the s-SPG/DNA complex 
meets the corresponding complementary sequence [e.g., s-SPG/poly(T) meets poly(dA)], 
and inhibition (or reduction) of non-specific interactions between bound therapeutic 
ODNs and serum proteins. They have been exploring this novel 
polysaccharide/polynucleotide complex and have proposed a new method to deliver 
DNA by using this complex. 
1.3 Spectroscopic changes upon complexation with poly(C) and s-SPG 
Figure 7 shows a comparison of the ultraviolet (UV) absorbance and circular dichroism 
(CD) spectra between poly(C) itself and the complex made from poly(C) and s-SPG 
(denoted as poly(C)/s-SPG). Here, the Mw (weight-average molecular weight) of s-SPG 
is 150 kDa and the cytosine base number is about 250. The complexation decreases the 
absorbance of cytosine at 270 nm by 12% (hypochromic effect), increases the CD 
intensity of the 275-nm positive band, and creates a new broad band at around 245 nm. 
Since SPG does not have any functional group to absorb the light within this 
wavelength range, the hypochromic effect of UV should be ascribed to decreasing 
distance between the stacked bases in the polynucleotides. Furthermore, the increment 
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of CD spectral intensity implies that the polynucleotide adopts an ordered helical 
structure even after complexation, and the content of the helical structure (or the 
ordering of it) is increased. Consequently, the complexation creates a new ordered 
helical structure of poly(C). This is in strong contrast to polycation/polynucleotide 
complexes, in which the CD spectrum is usually considerably suppressed due to random 
aggregation. 
They examined whether the other glucans show similar changes in the UV and CD 
spectra upon treatment in the same manner as described above. The results shown in 
Table 2 indicate that complexation is only observed for β-1,3-glucans. Although the 
data are not shown, no appreciable change was observed in the CD and UV spectra, 
even when the natural triple helix of SPG was mixed with poly(C). This shows that the 
renaturation process is indispensable for complexation.  
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Figure. 7 Comparison of the UV and CD spectra between poly(C) and 
poly(C)/s-SPG. 
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Table 1. Relationship between the capability to form the complex and the glucose 
linkage of natural glucans. (Permission obtained from Nature Publishing Group) 
 
  27 
I-5 Purpose of Thesis and Contents 
1.1 The formation of Crosslinked(CL)-ODN through DNA-DNA hybridization 
The particle size design for DDS is one of important point. In this research, the particle 
size was focused based on original ODN/SPG complex. The novel complex was created 
as a nanogel made from ODN/SPG complexes through DNA–DNA hybridization 
[crosslinked (CL)-ODN] based on a size-based nanocarrier. In Chapter II describes the 
formation of crosslinked (CL)-ODN consisting of β-glucan with ODN through DNA 
hybridization. (Figure 8A)  
1.2 CpG-ODN delivery and its immune activity for immune vaccine by the 
crosslinked(CL)-CpG/SPG complex 
CpG-ODN is known as a ligand of Toll-like receptor (TLR) 9 and strongly induces Th1 
responses. In Sakurai’s previous study, they developed a CpG-ODN delivery system by 
using CpG/SPG and demonstrated that CpG/SPG induces high Th1 responses. The 
CL-ODN include CpG-ODN (denoted CL-CpG) can deliver CpG-ODN to antigen 
presenting cells. In Chapter III describes cellular uptake of size-controlled CL-CpG and 
Its enhanced immunostimulation for cancer vaccine and antigen protein model in vitro. 
(Figure 8B) 
1.3 Cytosol delivery by use of TAT-ODN/SPG complex 
ODN/SPG complex protects anti-absorption of protein and the ODN is not degraded by 
enzyme. However the ODN/SPG doesn’t have ability of endosome escape. TAT peptide 
based on lysine rich sequence is well-known improvement target molecule for cellular 
uptake. For the cytosol delivery of ODN/SPG complex, TAT was conjugated with dA40. 
The synthesis was based on the crick chemistry. The result, the TAT/ODN/SPG 
complex was formed. In Chapter IV, the TAT/ODN/SPG complex was characterized 
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physical and observed distribution in the cell. The antisense (AS)-ODN effect with 
TAT/AS-ODN/SPG complex was measured in vitro (Figure 8C) 
1.4 A two-component micelle with emergent pH responsiveness by mixing 
dilauroyl phosphocholine and deoxycholic acid and its delivery of proteins into the 
cytosol 
Deoxycholic acid (DA) and its family, generally called bile acids, are known as typical 
steroid derivatives. The material has long history for medical application and 
well-known safety. However the material as a DDS doesn’t use. Sakaguchi et al. 
established a new pH-responsive nanoparticle made from dilauroyl phosphocholine 
(DLPC) and deoxycholic acid. In Chapter  , the pH-responsive properties of this 
system was cleared and to understand its mechanism of action at the molecular level. 
The resulting, the pH-responsive nanoparticle delivery protein to cytsol.(Figure 8D) 
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Figure8. The outline of these Chapters 
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Chapter II  
Crosslinked oligonucleotides(ODN)/β-1,3-Glucan 
Nanoparticle through DNA-DNA Hybridization.  
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II.1 Introduction 
The nanoparticle size depends on cells and endocytosis pathways, its range is normally 
a few hundred nm.1 In a design of nanoparticle for drug delivery, the size is one of 
important point. Sakurai et al. studies,2,3 there is a particular range in nanoparticle size 
suitable for cellular uptake. 
We have studied a polysaccharide schizophyllan (SPG), a member of β-glucans, as a 
delivery carrier of ODN since SPG can make a complex with specific homonucleotides 
such as poly(C) or poly(dA) via a combination of hydrogen bonding and hydrophobic 
interactions.4-6 As presented in Figure 1, two SPG chains and one polynucleotide chain 
form a triple helix through the binding between two main chain glucoses and one base. 
The complex can be recognized by Dectin-1 on APCs and then incorporated into the 
cells.2,3 Dectin-1 is a major receptor involved in the recognition of β-glucans on APCs, 
including macrophages dendritic cells, monocytes, neutrophils, and B cells. 7,8 Thus, it 
is expected that β-glucans can specifically deliver the bound ODN to APCs. We have 
reported that antisense ODN or short interference RNA complexed with SPG shows 
efficient gene silencing in animal models of fulminant hepatitis3,9 and bowl disease.10 
We also have prepared the complex made from CpG-ODN, which is adjuvant, and SPG 
(CpG-ODN/SPG) and attained the induction of robust immune response in vitro and in 
vivo.2,11 
Compared to these sizes, the present ODN/SPG is relatively small when we used SPG 
with a molecular weight of 150 K (ca., 10-20 nm in diameter). Therefore, the 
preparation of larger particles with ODN/SPG would enhance performance or add 
further functionality to the present system.  
  38 
II.2 Experimental 
2.1 Nanoparticle Preparation. 
SPG was dissolved in 0.25 N NaOHaq (1 N NaOH; Waco Inc., Osaka, Japan) for two 
days to dissociate the triple helix into single chains. Appropriate amounts of SPG 
solution, ODN in water, and phosphate-buffered solution (330 mM NaH2PO4, pH = 4.7) 
were mixed together. Then, this mixture (0.1 µM ODN, pH = 7.4) was stored at 4 °C 
overnight. The molar ratio of [SPG]/[ODN] was set at 0.27, where seven ODN units are 
contained in one complex on average. In the same manner, we prepared cODN/SPG. 
After complexation, ODN/SPG was mixed with cODN/SPG at different mixing ratios 
and incubated at room temperature overnight. The mixing molar ratio is denoted as 
CL-ODN (1:X), where X is the molar ratio of cODN/SPG to 1 molar ODN/SPG. We 
only used CL-ODN (1:1) for in vivo assays and the term CL-ODN refers to this 
equimolar mixture unless otherwise noted. 
2.2 Gel electrophoresis 
Nanoparticle was analyzed with 1% agarose gel electrophoresis at 4 °C. After the 
electrophoresis, ODNs were stained with SYBR Gold (Invitrogen, Carlsbad, CA). 
2.3 Physicochemical characterization 
Dynamic light scattering (DLS) at a fixed angle of 14–163° was measured with a 
Malvern Zetasizer Nano (Malvern Instruments, Malvern, UK) at room temperature. The 
obtained correlation function was converted to the size distribution. A level of solvent 
viscosity of 0.142 ml/g was used. Based on the obtained distribution, the 
number-averaged hydrodynamic radius (Rh) was determined. The concentration of the 
samples was approximately 2.6 mg/ml. Synchrotron small-angle X-ray scattering 
(SAXS) was measured for ODN/SPG and CL-ODN at the beam-line BL40B2 at 
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SPring-8, with a 2.0-m camera and an X-ray wavelength of 0.1 nm. The experimental 
details are reported elsewhere.12 The weight-averaged molecular weight (Mw) was 
determined using multi-angle light scattering (MALS) coupled with gel permeation 
chromatography (GPC).12 The ratio of double-stranded ODN to single strands was 
determined using the Quant-iT dsDNA BR Assay Kit (Thermo Fisher Scientific, 
Hudson, NH, USA). 
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II.3 Results and Discussions 
Creation and physiochemical characterization of CL-ODN nanogel  
One way to make a large particle is to use ODN portions as a crosslinking point. We 
mixed complementary ODN (cODN)- dA40/SPG and ODN-dA40/SPG at the same molar 
ratio and examined this mixture (denoted cODN-dA40/SPG + ODN-dA40/ SPG) with gel 
electrophoresis. Here, ODN-dA40 and cODN-dA40 sequences are 
ATCGACTCTCGAGCGTTCTC-dA40 and GAGAACGCTCGAGAGTCGAT-dA40, 
respectively; dA40 is necessary for binding to SPG. 
Figure 2A compares the 1% agarose gel electrophoresis migration patterns, where 
ODN-dA40 and cODN-dA40 were stained with SYBR Gold. The cODN-dA40/SPG and 
ODN-dA40/SPG showed smeary fluorescence bands at the larger molecular weight side 
than the original ODN-dA40 and cODN-dA40 did. No migration was observed for the 
ODN-dA40/ SPG + ODN-dA40/SPG, their fluorescence was retained in the wells, 
indicating that its molecular size was too large to move through the gel. Based on 
previous studies,2,3 we can presume that the ODN or cODN portions in the complex are 
not involved in the complexation with SPG and exist as a single strand, as presented in 
Figure 1A. Therefore, after we mixed cODN-dA40/ SPG and ODN-dA40/SPG, some of 
the ODN portions hybridize with the cODN portion and this hybridization should play 
the role of crosslinking points, resulting in larger particles than the original ones, as 
illustrated in Figure 1B. Hereinafter, we denote this component as crosslinked 
ODN-dA40/SPG nanoparticle. When ODN-dA40/SPG was mixed with 
non-cODN-dA40/SPG (i.e., scrambled sequence for ODN), the fluorescence was 
observed at the same position as with ODN-dA40/SPG. Another important conclusion is 
that there was no applicable amount of ODN-dA40/SPG and cODN-dA40/SPG 
fluorescence observed after mixing, indicating that the major component of 
  41 
cODN-dA40/SPG + ODN-dA40/SPG is the nanoparticle.  
Figure 2B shows a comparison of the size distribution between ODN-dA40/SPG and 
CL-ODN, obtained by DLS. Mixing ODN/SPG and cODN/SPG together was shown to 
increase the particle size more than ten times from Rh = 10.1 nm to Rh = 150 nm. This 
indicates that several crosslinks were formed owing to hybridization between ODN and 
cODN sequences in CL-ODN. The increased size as well as molecular weight was 
confirmed by MALS (Figure 2C), in which the main peak was found at an elution time 
of 20 min and Mw was determined by extrapolating the zero scattering angle using 
Berry’s plot. The values of Mw at the peak top were 5×105 g mol-1 and 2×107 g mol-1 for 
ODN/SPG and CL-ODN, respectively. Owing to a low signal intensity, the radius of 
gyration could not be determined accurately. Figure 2D plots Rh against the composition 
of the mixture. As expected, a ratio of ODN/SPG to cODN/SPG of 1:1 gave the highest 
Rh value. It is interesting that Rh increased exponentially as an equimolar composition 
was approached. Two conclusions can be drawn from this: First, the exponential 
increase is consistent with normal gelation theory or behavior, in which the molecular 
weight increases infinitely at the gelation point.13 Second, the ODN and cODN portions 
hanging out from SPG play roles in crosslinking the complex. The size or molecular 
weight at a mixing ratio of 1:1 remains finite because we carried out the mixing at a 
relatively low concentration. Therefore, gelation was confined to a certain spatial limit. 
In this sense, we can regard CL-ODN(1:1) as a nanogel particle similar to 
cholesterol/pullulan nanogels.14 
 
Our previous study12 showed that ODN/SPG complex (ODN/SPG) adopts the form of a 
semiflexible rod-like chain without branching, similar to the original triple helix of SPG. 
These two forms differ with regard to their flexibility: the complex is more flexible than 
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the triple helix of SPG, in terms of the persistence length: 200 nm for the SPG triple 
helix and 60 nm for the complex. Figure 3 double-logarithmically plots the SAXS 
intensity [I (q)] against the magnitude of the scattering vector (q) for renatured SPG, 
ODN/SPG, and CL-ODN. For all samples, intermediate q (0.1 nm-1<q<~0.7 nm-1, 
corresponding to 60–10 nm in real space) gives a scaling factor of α=-1 when we 
express q I (q) ∝qα. This means that the local conformation for CL-ODN shows a 
rod-like nature similar to the complex and SPG. Therefore, it can be concluded that the 
gelation with ODN/cODN hybridization does not interfere with the rod-like nature of 
the complex. In the low-q range (q<~0.1 nm-1), α becomes -2 for CL-ODN, while the 
others showed no change. This difference is due to the presence of a gel network in 
CL-ODN and the network size can be roughly estimated to be 60 nm. The inset of 
Figure 3 shows the cross-sectional Guinier plot for the high-q range (i.e., ln q I(q) vs. 
q2). From the slope, the cross-sectional radius of gyrations for all samples can be 
determined (the determined values are indicated in the inset). CL-ODN shows a slightly 
smaller cross-sectional size. This may be due to averaging of both the thick complex 
(~0.77 nm in diameter) and the thin double-stranded DNA (~0.72 nm). 
The double-stranded ratio was determined to be almost 100% with the BR assay, which 
reflects an absence of free ODN or cODN portions hanging out from the complex. This 
is consistent with the gelation behavior shown in Figure2D. Combining the above 
findings, we can depict the structure of CL-ODN as follows (also shown in Figure 1C). 
After mixing semi-flexible ODN/SPG and cODN/SPG, the free ODN and cODN 
portions form a DNA double helix at almost 100% yield; this double-stranded DNA 
plays a role in the crosslinking that results in gelation. The nanogel particle size is 
approximately 150 nm and the overall molecular weight is increased by 10 times. Based 
on this molecular weight, the number of crosslinking DNA can be estimated to be 35 
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per CL-ODN. Intermediate SAXS shows that the 60–10 nm local structure of CL-ODN 
is identical to that of ODN/SPG. This is an important conclusion because most 
molecular pattern recognition receptors recognize structures of this size. The unchanged 
local conformation was also confirmed by circular dichroism (see Figure S1). 
 
II.4 Conclusions 
In conclusion, we prepared a crosslinked nanoparticle consisting of ODN-dA40/SPG and 
cODN-dA40/SPG complexes through DNA-DNA hybridization. This nanoparticle was 
much larger and controlled the particle size by mixing complex ratio showed. The 
present study suggests that the crosslink complex can be used as a potent gene delivery 
to expression Dectin-1 cell.   
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II.5 Figures 
 
Figure 1. Schematic illustration of CL-ODN nanogel, with the chemical structure of 
SPG shown in A. The ODN/SPG and cODN/SPG complexes have a single chain of 
ODN or cODN hanging out from the dA40/SPG complex. (B) After mixing, 
hybridization between ODN and cODN leads to the formation of a nanogel. (C) In this 
nanogel, the characteristic semiflexible rod-like structure is maintained, which can be 
recognized by Dectin-1 and other β-1, 3-glucan receptors on APCs. The network size is 
determined to be 60 nm using small- angle X-ray scattering. 
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Figure 2. Increased molar mass due to crosslinking between ODN-dA40/SPG and 
cODN-dA40/SPG, observed with (A) 1wt % agarose gel electrophoresis. Particle size 
evaluation by DLS (B, D) and molecular weight determination by GPC coupled with 
MALS (C). The ODN/SPG and cODN/SPG mixing composition dependence of Rh, 
showing that gelation occurred at a ratio of 1:1. 
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Supporting Figure 1. The structural changes of ODN after complexation with SPG and 
nanogel formation. The circular dichroism spectra at 240–320 nm for ODN (red short 
dotted line), ODN/SPG (black long dotted line), and CL-ODN (black solid line) were 
measured at room temperature. 
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Chapter III  
Adjuvant activity enhanced by crosslinked 
CpG-oligonucleotides in beta-glucan nanogel and its 
anti-tumor effect  
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III.1 Introduction 
Several remarkable breakthroughs have been made in cancer immunotherapy in the last 
few years.1,2 Among them, promising levels of therapeutic efficacy have been reported 
in solid tumors by inhibiting T-cell checkpoint molecules such as PD-1 using 
monoclonal antibodies.3 Another breakthrough has been achieved by ex vivo 
engineering of T-cell therapy.4 Compared with these two approaches, cancer vaccines 
have failed to show convincing results regarding their efficacy in humans,5 although 
they have a long history in tumor immunotherapy since the mid-1990s.5,6 Recent 
immunological studies revealed that there are several factors behind this lack of success. 
According to the recent reviews,7 these factors are (1) poor antigenicity of tumor 
antigen, (2) heterogeneous expression of tumor antigen, (3) a lack of an optimal vaccine 
administration schedule and route, (4) how to choose a suitable adjuvant, and (5) an 
immunosuppressive status at both local and systemic levels. To improve the 
effectiveness of cancer vaccines, we need to develop a new vaccine system by taking 
these issues into account.8,9 
When an antigen is administered in the process of cancer vaccination, it is first taken up 
by phagocytosis of antigen-presenting cells (APCs) such as dendritic cells and 
macrophages. After fragmentation and modification, certain small antigen peptides are 
presented to CD8+ T cells and CD4+ T cells via major histocompatibility complex 
(MHC) molecules on the surface of APCs.10,11 The antigen/MHC complex is recognized 
by T-cell receptors of these two T cells and they eventually mature. The mature CD8+ T 
cells are essential for eradication of the tumor cells and are called cytotoxic T 
lymphocyte (CTLs). However, the addition of an antigen alone does not induce a 
sufficient immune response to attack cancer cells. Similar to other vaccines, there is a 
need to add an adjuvant that can modify the immune response by helping immature to 
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lead a mature. Ligands or agonists that can be recognized by Toll-like receptors (TLRs) 
3, 7, and 9 can be potent adjuvants.12-14 Among them, CpG oligonucleotides 
(CpG-ODNs) containing the immunostimulatory CpG motif are an excellent adjuvant 
and can activate APCs through binding to TLR9.15,16  
The outcome of CpG-ODN depends on its sequence and backbone.15,17,18 D-type 
CpG-ODNs (or CpG-A) contain a palindromic CpG sequence with phosphodiester (PO) 
backbones connecting with a poly(G)-tail with phosphorothioate (PS) backbones. 
CpG-ODNs are known to lead to the production of large amounts of IFN-α.19 Their 
biological outcome may be related to the tendency for the D-type to form large 
aggregates due to G-quartet-related intermolecular interactions, which may hamper 
clinical application owing to the side effect caused by its aggregation. Its aggregated 
structures are supposed to lead to high production of IFN-α.20 However, Aoshi et al.22 
recently found that non-aggregated D-type CpG-ODNs also led to an immune response 
similar to that with aggregated ones. Therefore, we suppose that the molecular and 
biological mechanisms of the response to D-type DNAs have not been established yet. 
It is still the case that their aggregation makes clinical trials difficult, unless the size and 
time-course stability are well controlled.21,22 K-type CpG-ODNs (or CpG-B) with PS 
contain multiple non-palindromic sequences and induce interleukin-6 (IL-6) and the 
maturation of plasmacytoid dendritic cells.15,23,24 K-type CpG-ODNs are soluble in 
aqueous solution, which does not impede clinical trials, and activate B-cells to produce 
IL-6, but does not produce a large amount of IFN-α. These CpG-ODNs can be an 
excellent candidate for an adjuvant for vaccination. However, they have several 
drawbacks that need to be overcome. One of the major problems is that CpG-ODNs are 
easily degraded by nucleases and excreted into the urine before being taken up by APCs. 
Phosphorothioate or other artificially modified nucleotide analogues may prevent such 
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degradation, but the chemical modification may cause side effects.25 Furthermore, a 
suitable delivery vehicle to transport the CpG-ODNs to APCs is needed to improve 
immunostimulatory specificity and immunotherapeutic efficiency.  
Recently, we have demonstrated that CpG-ODNs can be specifically delivered to APCs 
and stimulate human peripheral blood mononuclear cells to produce large amounts of 
both type I and II IFN, when CpG-ODNs are complexed with a beta-glucan SPG.26-29 
Here SPG is an abbreviation of schizophyllan, which is a member of the beta-glucans 
and comprises a main (1→3)-beta-D-glucan chain and a (1→6)-beta-D-glycosyl side 
chain that links to the main chain at every third glucose residue (Figure 1A). SPG forms 
a stoichiometric complex with specific homo-nucleotides such as poly(C) or poly(dA).30 
Furthermore, SPG and its complex with ODN can be specifically recognized and then 
taken up by certain Immunocytes. The great advantage of the CpG-ODN/SPG complex 
(CpG/SPG) is that, when K-type CpG-ODN was administered as an SPG complex, it 
led to the production of a large amount of IFN-α and CTL induction at the same time. 
The CpG-ODN is not necessary to bind to antigens. The drastic antigen-specific 
response can be obtained only upon co-administration of protein antigens.28,29 These 
novel and quite effective adjuvant properties are considered to be attributable to the 
nano-particle nature of the CpG/SPG complex.28 Therefore, in this study, we increased 
the particle size of the complex and examined its immune response and adjuvant effect 
as a cancer vaccine. 
APCs express several receptors to bind beta-glucans including Dectin-1, which explains 
why we can specifically deliver ODNs/SPG to them. According to recent studies, 
particle size, morphology, and surface characteristics are important factors to promote 
cellular uptake.31-33 This is especially true for phagocytic APCs. Bachmann et al. 
demonstrated that nanoparticles of 20–200 nm in size are likely to accumulate in 
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dendritic cells and macrophages residing in draining lymph nodes.34 In a Chapter 2 , 
ODN/SPG was determined to be approximately 10–20 nm in diameter,27 and this 
smaller size seemed to be less uptaking by APCs. We can thus expect that larger 
CL-ODN particles would enhance this uptake. In the chapter II,27 we reported a new 
concept of forming a larger ODN/SPG nanogel particle (denoted CL-ODN, where CL 
stands for crosslink) than normal complexes by using crosslinks between ODN/SPG and 
complementary ODN (cODN)/SPG complexes (cODN/SPG) through DNA-DNA 
hybridization. In the present study, which continues on from this previous work, we 
report that the including CpG-ODN of CL-CpG was examined the adjuvant efficiency 
of the cancer vaccine in vivo. 
III.2 Experimental 
2.1 Materials 
SPG (M_w= 1.5 × 105 as a single chain) was kindly provided by Mitsui Sugar Co., Ltd. 
(Tokyo, Japan). All DNAs were synthesized by Gene Design Inc. (Osaka, Japan) and 
purified using high-performance liquid chromatography. In this study, we used a PS 
instead of a PO for dA since PS-dA forms a stable complex with SPG compared with 
PO-dA.35 The sequences of CpG and cCpG are ATCGACTCTCGAGCGTTCTC-dA40 
and GAGAACGCTCGAGAGTCGAT-dA40. EndoFitTM ovalbumin (OVA) was 
purchased from InvivoGen (San Diego, CA, USA). As an antigenic peptide, an OVA 
peptide (SIINFEKL, amino acids 257–264 from OVA; OVA257–264) was synthesized 
by Gene Design Co., Ltd. IL-6 and IFN-γ ELISA kits were purchased from eBioscience, 
Inc. (San Diego, CA, USA). 
2.2 CL-CpG/SPG preparation 
SPG was dissolved in 0.25 N NaOHaq (1 N NaOH; Waco Inc., Osaka, Japan) for two 
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days to dissociate the triple helix into single chains. Appropriate amounts of SPG 
solution, CpG in water, and phosphate-buffered solution (330 mM NaH2PO4, pH = 4.7) 
were mixed together. Then, this mixture (0.1 µM CpG, pH = 7.4) was stored at 4 °C 
overnight. The molar ratio of [SPG]/[CpG] was set at 0.27, where seven CpG units are 
contained in one complex on average.27 In the same manner, we prepared cCpG/SPG. 
After complexation, CpG/SPG was mixed with cCpG/SPG at equal molar ratios and 
incubated at room temperature overnight.  
2.3 Cells lines 
RAW 264 (a murine macrophage cell line from blood) and E.G7-OVA cells 
(OVA-transfected EL4 thymoma cells) were purchased from American Type Culture 
Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium (Waco Inc., 
Osaka, Japan) at 37 °C in 5% CO2. 
2.4 Uptake of fluorescein isothiocyanate (FITC)-labeled SPG into immune cells 
FITC-labeled SPG (denoted f-SPG) was prepared by a previously reported method and, 
on average, FITC was attached to one of every 13 glucoses on the main chain.36,37 We 
confirmed that attachment of FITC at this low level did not interfere with any 
characteristics of the complex. An f-SPG solution of 7.5 µg/mL was added to 4 × 104 
cells/96-well plate. After the indicated times, cells were washed twice with PBS, stained 
with 4′, 6-diamidino-2-phenylindole, and the cellular image was observed with a 
BZ-9000 fluorescence microscope (Keyence Co., Osaka, Japan). For the measurement 
of fluorescence intensities, the homogenates were prepared with lysis buffer. The 
fluorescence intensities and protein concentrations were measured with a Wallac 1420 
(PerkinElmer, Wellesley, MA, USA) and a Protein Quantification Kit (Dojindo, 
Kumamoto, Japan), respectively.  
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2.5 Mice 
All mouse experiments were performed in accordance with the guidelines of the Animal 
Care and Use Committee of the University of Kitakyushu. Seven-week-old male 
C57BL/6J mice were purchased from Japan SLC, Inc. (Shizuoka, Japan). 
2.6 Cytokine secretion assay 
Mouse splenocytes were seeded at 1.0 × 106 cells/96-well plate and supplemented with 
the indicated adjuvants at 200 nM. After 24 h, IL-6 concentrations in the supernatants 
were measured with a mouse IL-6 ELISA kit. 
2.7 Formation of OVA-specific CD8+ cells 
Mice were intradermally immunized with OVA (30 µg) combined with CpG, CpG/SPG, 
or CL-CpG (CpG; 15 µg for all experiments and the DNA dose was fixed at the same 
amount for the naked and complex administration) at day 0 and day 10. After the 
collection of mouse splenocytes at day 17, the cells were stimulated with OVA257–264 
at 10 µg/ml for 24 h. The supernatants were subjected to ELISA to detect mouse IFN-γ. 
For the quantitative determination of OVA-specific CD8+ cells, splenocytes were 
stained with H-2Kb OVA tetramer (MBL Co., Ltd., Nagoya, Japan) and anti-CD8 
antibody (BD Pharmingen, San Diego, CA, USA). The population of OVA tetramer+ 
CD8+ cells was determined with an EPICS® XL flow cytometer (Beckman Coulter, 
Fullerton, CA, USA). 
2.8 Formation of OVA-specific CD8+ cells Tumor growth assay 
Mice were pre-immunized with a mixture of OVA and naked CpG, CpG/SPG, or 
CL-CpG on days −17 and −7 before inoculation with 1.0 × 106 E.G7-OVA cells in the 
left flank on day 0. The tumor size was monitored by measuring two axes of the tumor 
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using digital calipers every two to three days. The tumor volume was calculated as 
follows: “minor axis2 × major axis × 0.5”. Once the tumors had reached 2.5 cm3 in 
volume, the mice were sacrificed by CO2 inhalation. 
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III.3 Results and Discussions 
Cellular uptake of CL-CpG 
Figure 1A shows the time course of fluoresense microscopic imaging of the RAW 264 
cells upon the addition of CL-CpG containing f-SPG [denoted CL-CpG(f)] or 
CpG/f-SPG. The green fluorescence color originating from FITC became detectable 
after 4 h, increased its intensity with the passing of time, and reached a maximum after 
8 h. At this stage, CL-CpG(f) was uniformly distributed in all of the cells. Figure 1B 
plots the fluorescence intensity against time, showing that CL-CpG(f) exhibited almost 
ten times greater intensity than f-SPG and CpG/f-SPG after 24 h. These results indicate 
that there is a preference for CL-CpG(f) uptake rather than CpG/f-SPG uptake. It is well 
known that APCs express various receptors including Dectin-1 that can specifically 
bind to beta-1, 3-glucans,38,39 and ODN/SPG complex is also recognized by Dectin-1 
with the same extent with SPG.26,40 Therefore, the increased uptake of CL-CpG can be 
ascribed to increased interaction between beta-1, 3-glucan binding receptors and 
CL-CpG. In this context, the main cause of this increase is of interest. Figure 1C shows 
a comparison of the fluorescence images after 4 h for different mixing ratios. This 
indicates that the cellular uptake peaks at a mixing ratio of 1:1. The structural analysis 
showed that mixing CpG/SPG and cCpG/SPG does not change the local conformation 
from the range of 10–60 nm, which is a size range normally recognized by pattern 
recognition receptors. Therefore, we can state that the binding affinities of the receptors 
are identical. Judging from the size change shown in Figure 2B, we can conclude that 
the increase in size is the essential factor for enhancing the cellular uptake. We can 
expect that, after internalization, the local concentration of CpG-ODN in the endosomal 
compartment should be higher than that of CpG/SPG. Since a higher concentration of 
ligands leads synergistically to an enhanced response in biological systems, the high 
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uptake may be better for adjuvant. 
Lee et al. have demonstrated that multiple-glycoside binding to receptors on the cell 
surface drastically enhances binding affinity.41 This is called the sugar-cluster effect and 
means that more binding sites normally allosterically result in more enhanced affinity.42 
The gel-network structure and increased molecular weight of CL-CpG may provide 
more binding sites than CpG/SPG. Furthermore, the morphology of the molecules plays 
a significant role in cellular uptake.43 Given that anisotropic bacteria, such as those with 
a rod-like shape, are more likely to be taken up by cells, numerous researchers have 
developed drug carriers mimicking the bacterial morphology.44 We assume that this 
morphological effect may also be involved in increasing the uptake of CL-CpG. 
Further in vitro assays to optimize the adjuvant effects 
Dependence of cytokine secretion on mixture composition 
Single-stranded CpG-ODN is recognized by TLR9 in late endosomes.15 The dsDNA BR 
assay shows almost no single-stranded CpG-ODN for CL-CpG (1:1). No dissociation of 
the double strands of CpG/cCpG by the breaking of crosslinks was observed at pH 5.5, 
which matches the conditions in late endosomes (see Figure S1). 
Because of this, we assumed that CL-CpG (1:1) would not induce any biological 
response related to TLR9 and there would be an optimal composition other than 1:1 that 
is determined by comparing the uptake in Figure 1C and decreasing amount of single 
CpG chain upon changing the mixing ratio. Contrary to this expectation, the IL-6 
secretion level peaked at a mixing ratio of 1:1, as shown in Figure 2. In the following 
experiments, we only used CL-CpG (1:1) for biological assays because of its highest 
uptake and cytokine secretion, suggesting that it has the most suitable composition for a 
beneficial adjuvant effect. 
  60 
The result shown in Figure 2 was unexpected and thus a more detailed discussion may 
be needed because there is no single chain of CpG sequence that can bind to TLR9. 
According to recent studies,45 there are various types of nucleic sensor other than TLR9 
in APCs. Some of them bind to double-stranded non-immunogenic DNAs and induce 
immune responses. One possible explanation for the result of Figure 2 is that the highly 
concentrated DNA due to the high uptake of CL-CpG may interact with these DNA 
sensors. Another possibility is that this is still a TLR9-initiated response. We suppose 
that, when the concentration of CpG/cCpG double strands is increased in the endosomal 
compartment, the equilibrium between CpG/cCpG and CpG/TLR9 may be shifted 
toward CpG/TLR9 formation. This is simply because the competition between these 
two species follows the law of chemical equilibrium, namely, increased [CpG/cCpG] 
leads to the formation of CpG/TLR9. Nishikawa et al. found similar behavior for 
polypod-like structured DNA.46 They exposed immune cells to polypod-shaped 
double-stranded DNA containing a CpG sequence and found that the polypod-shape 
enhanced uptake to induce the secretion of a large amount of cytokines. Later, they 
found that this event was triggered through TRL9.47 Their result is also explained by the 
increased concentration of CpG double helix and then the equilibrium shift.48 
 
Chemical structure of CpG-ODN backbone (PS or PO) and immune response 
We examined how the difference between PS and PO affects IL-6 secretion, the results 
of which are presented in Figure 3. CL-CpG(PO) induced pronounced IL-6 secretion, 
which was almost five times greater than that of CpG(PO)/SPG. Contrary to PO, 
CL-CpG(PS) is lower than naked CpG(PS). It has been clearly demonstrated that TLR9 
only binds to single-stranded DNAs that contain CpG portions and does not show any 
affinity to double-stranded DNA. We confirmed that CL-CpG(PO) and CL-CpG(PS) 
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have almost the same size and they are ingested by immune cells at the same levels. The 
large difference in the IL-6 secretion between them as shown in Figure 3 can be 
explained by two possible scenarios. First, the natural type PO double strands can be 
recognized by other DNA sensors,49 but the PS ones cannot. Second, the PS sequence 
may form a less stable complex with TLR9 than that of PO50 and, owing to this 
difference in stability, the formation of the TLR9/CpG(PO) complex can occur more 
frequently than that of TLR9/CpG(PS) when CpG double strands and TLR9/CpG are at 
equilibrium. Once the population of TLR9/CpG exceeds a certain critical concentration, 
the resultant biological response may be dramatically enhanced due to an allosteric 
effect. We have not obtained any results enabling us to draw conclusions on which of 
these reasons is more likely, but we only use CL-CpG(PO) in the subsequent analyses. 
Adjuvant activity of CL-CpG nanogel 
Figure 4A shows a comparison of the populations of OVA-specific CD8+ cells when 
naked CpG, CpG/SPG or CL-CpG was injected as an adjuvant for OVA vaccine. 
CL-CpG induced more CTLs than the others, indicating that the co-administration of 
OVA and CL-CpG efficiently increased the population of CTL. Figure 4B more clearly 
demonstrates the enhanced CTL activity, indicating that the secretion of IFN-𝛾 was 
dramatically increased only for CL-CpG. Here, IFN-𝛾 secretion is one of the criteria for 
the formation of CD8+ T cells. The cytokines including IFN-𝛾 are called Th1 cell 
cytokines and induce macrophages and CTLs to attack tumor cells. 
 
After the transplantation of E.G7-OVA cells that express OVA antigen on their surface 
into mice, we examined how CL-CpG+OVA prevents tumor growth (Figure 5A) and 
extends the survival of mice (Figure 5B), compared with CpG/SPG+OVA, CpG +OVA, 
and OVA alone. Figures 5A and 8B clearly demonstrate that CL-CpG+OVA is 
  62 
markedly superior to the others. Incidentally, we had already shown that the strong CTL 
responses were created by CpG/SPG+OVA,28,29 with the dose levels of ODN at 30 
µg/head and OVA at 100 µg/head. In this study, compared with the previous ones, we 
decreased the dose level (ODN at 15 µg/head, OVA at 30 µg/head) because 
CL-CpG+OVA showed an excellent response at this low dose. However, the decreased 
dose may have caused a smaller difference between CpG/SPG+OVA and naked 
CpG+OVA. As we reported previously,29 CpG/SPG+OVA improves the vaccine 
efficacy compared with CpG+OVA. We considered that this improvement is due to the 
APC targeting ability of CpG/SPG, while CpG has no such ability. CL-CpG showed 
further improvement compared with CpG/SPG. Presumably, this is related to its 
increased uptake, as shown in Figure 1. 
Figures 5C and 5D present the dependence of tumor growth and survival on the 
CL-CpG dose. Despite some experimental error, we can conclude that CL-CpG+OVA 
vaccine is still effective even when the dose is reduced to 0.2 µg/head, where we fixed 
the OVA dose of 10 µg/head. Adjuvant efficacy of CpG-ODNs has been studied for the 
last 5 years and numerous papers on this topic have been published.29 According to 
these previous studies, it is normally necessary to administer CpG at a dose of at least 
30 µg/head. In these cases, CpG-ODNs were injected in a naked state. Compared with 
the efficacy at this dose, we achieved the same efficacy at almost one-hundredth of the 
dose. Additionally, in terms of the active adjuvant ingredient, our CpG contains 33.3 
wt% of CpG in the total sequence. When we compared the efficacy on the basis of the 
CpG portion weight, 0.2 µg/head ODN corresponds to 0.07 µg/head CpG portion 
because our CpG-ODN has a dA40 tail. Therefore, again, to induce sufficient immunity, 
most previous studies51-55 required CpG-ODN at more than 10 µg/head; compared with 
them, we can achieve similar immune responses at a far lower dose (i.e., 0.07 µg/head 
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CpG). 
In our previous study, we observed IFN-α production upon the stimulation of human 
peripheral blood mononuclear cells with K-type CpG/SPG. Furthermore, we 
demonstrated that K-type CpG/SPG acted as an influenza vaccine adjuvant in a 
nonhuman primate model using cynomolgus monkey. Considering these findings, 
CL-CpG can be also applied to adjuvant for primate immunity, so it would be next issue 
to examine for primate, especially human, cancer model.  
Numerous studies have focused on the conjugation of antigenic proteins to 
adjuvants.54,55 Stayton et al. attached CpG to proteins and obtained a drastic 
enhancement of antigen-specific immune response.56 However, the present study shows 
that such conjugation or encapsulation of antigenic proteins is not necessary because of 
the accumulation and activation of antigen-bearing macrophages and dendritic cells in 
the draining lymph node, as shown in our previous study.28 We can instead obtain 
better or equivalent efficacy than CpG-protein-conjugated vaccines simply by 
co-administering CL-CpG and OVA. We believe that this is a major advantage. For 
example, the chemical procedures to achieve conjugation are not required, and thus we 
do not have to perform purification or attempt to maximize the reaction yield for the 
conjugation. In addition, CL-CpG co-administration can be used for other vaccines such 
as for influenza to enhance their efficacy. This expansion of the range of applications is 
relatively easy because it only requires mixing of CL-CpG and vaccines. 
III.4 Conclusions 
We prepared a crosslinked nanogel consisting of CpG/SPG and cCpG/SPG complexes 
through hybridization between CpG and cCpG portions. The double-stranded CpG with 
PO induced a strong immune response, while those with PS did not. Immunization with 
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a mixture of CL-CpG and OVA induced antigen-specific CTL activities both in vitro 
and in vivo. These results can be attributed to the improved cellular uptake due to 
increased size, the cluster effect of the sugar recognition sites, and the subsequent high 
concentration of CpG-ODN in the endosomal compartment. Therefore, CL-CpG has 
great potential as a potent vaccine adjuvant for the treatment of cancers and infectious 
diseases.  
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III.5 Figures 
 
Figure 1. Uptake of CL-CpG into the RAW 264 cells. After adding CL-CpG(f) and 
CpG/f-SPG, the RAW 264 cells (A) were observed by fluorescence microscopy. The 
fluorescence intensities were plotted against time at the RAW 264 cells (n = 3)(B). **P 
< 0.01. The dependence of the level of FITC uptake on the CpG/f-SPG and 
cCpG/f-SPG mixing ratio with mice peritoneal macrophages is also presented, showing 
that the highest ingestion was obtained at a ratio of 1:1. (C) 
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Figure 2. The dependence of IL-6 secretion on the CpG/SPG and cCpG/SPG mixing 
ratio in mouse splenocytes. *P < 0.05. **P < 0.01. 
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Figure 3. Different CpG-ODN backbones (PO and PS) and the IL-6 secretion response. 
The samples were added to mouse splenocytes at 200 nM. Results are presented as 
mean ± S.D. (n = 3). **P < 0.01. 
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Figure 4. Induction of potent CTL activities by immunization with CL-CpG. 
OVA-specific CD8+ T cells (A) and IFN-γ production (B) were measured after 
immunization with OVA (30 µg/head) and the indicated adjuvants (A and B: ODN; 15 
µg/head). Results are presented as mean ± S.D. (n = 4). *P < 0.05. 
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Figure 5. Immunization with a mixture of CL-CpG and OVA to suppress tumor growth. 
Before translated OVA peptide-bearing tumor cells, on days −17 and −7, mice were 
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immunized with OVA (10 µg/head) and the indicated adjuvants (ODN; 5.0 µg/head). 
Changes in tumor volume (A) and mortality (B) were monitored after tumor inoculation 
(n = 4). Upon immunization with OVA (10 µg/head) and CL-CpG (ODN; 0.05, 0.20, 
0.50, 1.60, 5.0, or 10 µg/head), changes in tumor volume (C) and mortality (D, E) were 
monitored after tumor inoculation (n = 4). 
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Figure S1. The stability of CL-CpG under conditions matching those in late endosomes. 
The CL-CpG was incubated at the indicated pH for 1 h and subjected to agarose gel 
electrophoresis.   
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Chapter IV  
A beta-glucan/ODN carrier conjugated with TAT 
peptide: Specific delivery to cytosol 
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IV-1 Introduction 
Antisense oligonucleotides (ASOs) are single-stranded nucleic acids consisting of 15–
25 nucleotides in length, which bind to the target mRNA sequence specifically, 
resulting in interference with gene expression. ASOs can modulate gene expression by 
several mechanisms including RNase H-mediated degradation of the target RNA1,2 or 
skipping of the targeted exon and altering the RNA and protein sequence.3 One of the 
major obstacles for clinical application of ASOs is enzymatic degradation in vivo. From 
first introduction by Zamecnik et al.,4 chemical modifications to the backbone have 
been at the center of research interest for improvement of stability in vivo. Among 
chemical modifications, phosphorothioate (PS) backbone that replaced one of the 
nonbridging oxygen atoms in the phosphodiester backbone with a sulfur atom is termed 
the first generation of oligonucleotide modifications and reported to show a high 
stability in serum.5 Despite the benefit, there is room for consideration of cellular uptake. 
Thus, the efficient and non-toxic delivery systems have been developed by many groups, 
including liposomes and cationic polymer complexes. In our previous study, we have 
found oligonucleotide (ODN) delivery system by complex of polysaccharide 
Schizophyllan (SPG) and ODN. Our group have studied a beta glucan, Schizophyllan, 
in short, SPG as a ODN carrier. When SPG in alkaline solution is neutralized with some 
of single chain homopolynucleotides such as poly deoxyadenylic acid (polydA) forms 
ODN/SPG complex. 6,7 In particular, PS-polydA is a stronger binding affinity to SPG 
than phosphodiester (PO) backbone-polydA.8  The SPG is one of beta-glucan and 
recognized Dectin-1 of beta-glucan receptor. We have demonstrated that Dectin-1 
recognizes SPG/ODN complexes and shows a high stability in serum,9 and the complex 
is eventually ingested by the cells and transports functional ODN including antisense 
(AS)-ODN, CpG-ODN, and siRNA to expressed Dectin-1 cells.10-13  
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Among the various proposed delivery carriers, cell-penetrating peptides (CPPs) have 
much attention as the most promising carrier for internalization into cells.14 
Ryser and his colleagues first demonstrated that conjugation of cationic peptides to 
anticancer drugs can improve cellular uptake in vitro and in vivo.15 Most CPPs, small 
and basic amino acids-rich peptide as shown in HIV-1 Tat protein, are found to have the 
ability to translocate across cellular plasma membranes.16,17 Therefore they are often 
used by covalent conjugation with drugs or drug-embedded carriers. In case of 
conjugation with oligonucleotides (ODNs), a disulfide, ester and peptide bonds are 
employed. Among the conjugations, a disulfide bond between peptide with cysteine 
residue and maleimidemodified ODNs is largely advantageous because a disulfide 
linkage is dissociated in the reducing milieu, resulting in release of ODN from 
peptide.18 Although there are many reports concerning the synthesis of peptide-ODN 
conjugates (POCs) comprising a peptide and an ODN with phosphodiester backbones, 
only few papers describe the preparation of POCs with PS backbones (POCPs).19 Since 
the ODNs with PS backbones can induce a side react with a peptide bearing a disulfide 
reactive functional group, it is difficult to purify and evaluate the characterization of 
POCPs linked at the desired sites. Azhayev and his colleagues reported 
well-characterized POCPs using a PS-ODN with a mercaptoalkyl group and a peptide 
with a pyridyl disulfide function.20 ‘Click Chemistry’ is a concept of chemical reaction 
introduced by Sharpless at el. in 2001.21 Azide alkyne Huisgen cycloaddition using a 
copper catalyst is one of the most popular reactions and can be proceeded in benign 
reaction conditions and give high yields.22 In study, we synthesized POCPs with a 
simple reaction, where the POCPs comprise one of the major CPPs, Tat peptide, and 
PS-modified dA40 (PS-dA40) and formed with SPG/AS-ODN complex. The 
SPG/ODN/POCPs was observed into cytosol and examined the inhibition effect of cell 
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growth by treatment with AS-ODN for four human EGF receptor3 (HER3) that is good 
targeting for cancer therapy.23  
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IV-Results and Discussions 
We prepared PS-dA40 with alkyne group at 50-terminus and Tat peptide with azide 
group at C-terminus (Fig. 1A), and mixed the both compounds at various molar ratios 
with copper catalyst for the optimization of reaction condition. After the reaction, we 
soon added a chelate agent ethylenediaminetetraacetic acid (EDTA) to prevent the 
aggregations because PS-dA40 is considered to be easy to crosslink via cupper molecules. 
To confirm the conjugation, the reaction mixture was analyzed with high-performance 
liquid chromatography (HPLC). (Fig. 1B) From the chromatograms monitored by UV 
absorbance at 260 nm before and after the reaction, the peak of PS-dA40 shifted to an 
earlier elution time, indicating the increment in hydrophilicity of PS-dA40 by 
conjugation with Tat peptide (Tat-dA40). 
Figure 2 compares the gel permeation chromatograms (GPC) for Tat-dA40 with 
ODN/SPG complex. Here, only nucleotides (i.e., Alexa 546 modified-dA40 (Ale or 
Ale-dA40)) can be detected at 22 min. The complexation samples caused the UV peak at 
260 and 546 nm to shift from 20 to 15 min. At the UV at 260 nm, all ODNs were 
detected. On the other hand, the Ale-dA40 was detected at UV at 546 nm. At the 
calculated Tat-dA40 ratio in a complex, the molar of Tat-dA40 followed the change 
amount. (Table1) 
Figure 3A. shows uptake and localization of TAT complex in PC9 cell, a human lung 
cancer cell line. The PC9 is expressing Dectin-1 of beta glucan receptor. The Tat/FITC 
–modified dA40 (FITC)/SPG (0:7:2) and (5:2:2) were observed the fluorescence at 
indicated 8 and 24 hours. Then the two complexes were added at the same concentration.  
The green shows FITC-modified dA40 and blue are nuclear stained by DAPI. Tat/ 
FITC/SPG (5:2:2) was taken up by the cells in a time-dependent manner. At 24 hours, 
the fluorescence of Tat/ FITC/SPG (5:2:2) was higher than Tat/ FITC/SPG (0:7:2). This 
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result indicates TAT peptide certainly promotes the internalization to cells. 
Some papers reported TAT peptide acts to go to nuclear. So we mainly observed 
localization of TAT complex around nuclear. Figure 3B. was observed line scanning 
profiles, Tat/ FITC/SPG (0:7:2) and  Tat/ FITC/SPG (5:2:2) does not overlap with 
DAPI. The ODN/SPG complex with TAT exists in cytosol, not nuclear.  
Figure 4 shows the cell proliferation rates after treatment with Tat/dA40/AS-HER3/SPG. 
The treatment with Tat/dA40/AS-HER3/SPG (5:0:2:2) suppressed the cell proliferation 
of PC9 cells, while that with the naked AS-HER3 and other samples did not show any 
suppression. The result suggests that Tat peptides of Tat/dA40/AS-HER3/SPG can 
improve the cellular uptake to cytosol and suppress the target gene expression.  
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IV-3 Conclusions 
In the field of drug development, the application of Click Chemistry is increasing for 
exploration of useful compounds. The most of the researches use the reaction 
concerning the formation of a tria-zole ring by use of copper catalyst. In this study, We 
prepared Tat peptide conjugate phosphorothioate dA40 oligonucleotide (Tat-dA40) by the 
click chemistry reaction. The Tat-dA40/AS-HER3/SPG complexes showed a higher cell 
uptake and more cell-growth suppression than AS-HER3/SPG complex that had not Tat. 
We suppose that this improvement can be ascribed to Tat-induced cellular ingestion of 
the complexes.   
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IV-4 Figures 
 
 
Figure 1. (A) Synthesis of Tat-dA40: click chemistry reaction. (B) Confirmation of the 
conjugation between alkyne-modified PS-dA40 and azide-modified Tat peptide, and 
purification of the conjugate by HPLC. 
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Figure 2. Confirmation of the complex at changing molar ratio between Tat-dA40 and 
ODN in SPG were detected by GPC. 
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Table 1. The molar ratio of Tat-dA40 and Ale-dA40 in SPG 
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Figure 3. (A) Uptake of Tat/FITC-modified-dA40(FITC)/SPG into the PC9 cells. After 
adding Tat/FITC/SPG, the PC9 cells (A) were observed by fluorescence microscopy 
and (B) detected the line scanning of cell. 
  
  91 
 
Figure 4. Inhibition of cell proliferation by treatment with Naked AS-HER3, 
Tat/dA40/AS-HER3/SPG(5:2:0:2), (0:5:2:2), and (5:0:2:2). Results represent the mean ± 
SD (n = 3). **P < 0.01. 
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Chapter V 
A two-component micelle with emergent pH 
responsiveness by mixing dilauroyl phosphocholine 
and deoxycholic acid and its delivery of proteins into 
the cytosol  
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V-1 Introduction 
Drug-delivering nanoparticles are nanomachines or nanovehicles for transporting 
therapeutic agents into the targeted site in biological systems. Such nanoparticles are 
constructed by polymeric materials, lipids, or even biocompatible inorganic materials. 
When the target site is located inside cells, which is the case for antigen proteins (or 
peptides) and therapeutic nucleotides, endosomal escape, namely, the evasion of 
lysosomal trapping and degradation to promote release of the cargo into the cytosol 1, is 
one of the most important functions for a drug delivery system (DDS). Many 
nanoparticles have been designed to achieve this. Several chemical functional groups, 
including peptides to form pores on the endosomal membrane, protonatable groups to 
induce a pH-buffering effect, and a functional group to induce fusion into the 
endosomal bilayer, have been proposed to facilitate endosomal escape 2. Among these 
alternatives, polycations such as polyethylenimine and poly(L-lysine) have been used, 
with the expectation that they have a certain pH-buffering effect, called the “proton 
sponge hypothesis” 3. Since amines in these polymers are basic (pKa is 8-9), they can 
absorb the protons while avoiding the acidification of endosome; as protons are coming 
with Cl-, which is hydrated, the influx of Cl- and associated water ruptures the 
endosomes, which finally causes release of its cargo into the cytosol. The proton sponge 
hypothesis has been challenged because of a lack of concrete experimental evidence 4. 
Although the proton sponge effect may not be a correct mechanism, it is clear that 
pH-responsive nanoparticles are still a major factor in transporting cargo to intracellular 
targets. The target of pH-responsive nanoparticles is not only the cytosol, but also 
around cancer’s environment5. Several pathological conditions, including cancer, 
ischemic stroke, inflammation, and atherosclerotic plaques, are related to metabolic 
activity and hypoxia, leading to decreasing pH in the vicinity6. Therefore, these sites 
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can be other major targets of pH-responsive DDS. Recently, Maeda et al. proposed an 
effective DDS for pirarubicin (or 4′-O-tetrahydropyranyl adriamycin) by combining the 
enhanced permeability and retention effect and a pH-responsive imine bond 7. 
Many pH-responsive nanoparticles have been reported for DDS applications. Among 
them, cationic lipids after mixing with helper lipids, such as 
dioleoyl-phosphatidylethanolamine (DOPE) or cholesterol, are normally used. The 
effects of DOPE on destabilizing endosomal membranes and mediating endosomal 
escape have been discussed in many papers 8,9 and books 10. The potential for the cargo 
to be released into the cytosol means that many biological events can be induced. As 
one example, when protein antigens were the cargo, a fragmented peptide-MHC I 
complex stimulated CD8+ T cells and a cellular immune response including cytotoxic T 
lymphocyte activity, which is the most important event in cancer immunotherapy. In the 
case of therapeutic oligonucleotides such as antisense DNA and siRNA, silencing of the 
specific gene that is targeted by the oligonucleotides would occur. Our previous work 
showed that the pH-responsive range for inducing a structural transition of the 
nanoparticles strongly depends on the DOPE content and, when its transition pH 
matches the pH at which a change from early to late endosome occurs, the delivery 
efficiency reaches its maximum. Although DOPE-containing liposomes have been 
shown to be quite effective in some in vitro systems 10,11, in vivo study is different. It has 
been reported that DOPE causes unfavorable side effects including savior toxicity in 
organs and cells 12. Many other studies have adopted a similar pH-responsive strategy in 
designing nanoparticles 13,14. In most of these studies, a new material or functional 
group was attached to provide the pH responsiveness. Although these worked 
adequately, new materials are sometimes associated with safety issues, so there would 
be a larger barrier to fulfill legal requirements for medical usage. 
  99 
Sakaguchi et al. established a new pH-responsive nanoparticle made from dilauroyl 
phosphocholine (DLPC) and deoxycholic acid (DA) 15. Deoxycholic acid and its family, 
generally called bile acids, are known as typical steroid derivatives that are secreted 
from the gallbladder to emulsify dietary fats, fat-soluble vitamins, and other hydrophilic 
compounds. They are known as a controlling signal molecule for homeostasis, 
glycometabolism, lipid metabolism and energetic metabolism16,17. In the body, they 
play a role in promoting absorption, among others. Because of their origin, they are not 
associated with any serious toxicities18. Among the bile acids, DA and ursodeoxycholic 
acid have been approved as pharmaceutical additives for injection into humans 19. In 
addition, DLPC is one of the major lipids constituting cellular membranes and has a 
rather long history of clinical use 20,21. Therefore, the DLPC/DA system is expected not 
to have any issues regarding toxicity and unfavorable side effects. The aim of the 
present paper is to clarify the pH-responsive properties of this system and to understand 
its mechanism of action at the molecular level. 
V-2 Experimental 
2.1. Materials 
Egg yolk phosphatidylcholine (EYPC; COATSOME NC-50 grade) and DLPC 
(COATSOME MC-1212 grade) were obtained from NOF Corporation. DA was 
obtained from Tokyo Chemical Industry Co., Ltd. Ovalbumin-conjugated fluorescein 
(F-OVA) was purchased from Invitrogen (Carlsbad, CA, USA). Lyso Tracker® Red 
Lysosomal Probe was purchased from Lonza Walkersville, Inc. (Walkersville, MD, 
USA). The preparation of the DLPC/DA micelles was described in a preceding patent 
application, but it can be briefly summarized as follows: 1000 nM DLPC was dissolved 
in methanol and DA was also dissolved in methanol. After mixing them at a given ratio, 
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the solvent was evaporated. MES buffer (MES: 25 mM, NaCl: 125 mM, pH 7.4) was 
added after evaporation and dispersed using ultra-sonication.  
2.2. Characterizing pH responsiveness: interaction with a model membrane:  
In accordance with a previously reported method, the nanoparticle/liposome membrane 
interaction was examined. First, we prepared an EYPC liposome encapsulating pyranine 
as a fluorescent dye, with controlled sizes (ca. 100 nm) using a polycarbonate film with 
a pore size of 100 nm. After the outer water layer had been substituted by an MES 
buffer (MES: 25 mM, NaCl: 125 mM, pH 7.4), we added a nanoparticle solution and 
adjusted the final pH. The final concentration of DLPC and DA were 6.67 µM and 1.07 
µM, respectively. The leakage of pyranine was monitored with a fluorescence 
spectrometer (Jasco Co., Tokyo, Japan) .  
2.3. Dynamic light scattering  
The zeta potential (ζ) and the hydrodynamic radius (𝑅!) were determined for the 
samples in a HEPES buffer (HEPES: 1.0 mM) whose pH was adjusted to 7.4 with a 
Nano ZS 90.  
2.4. Synchrotron small-angle X-ray scattering (SAXS) 
The SAXS measurements were performed at BL-40B2 of SPring-8, Japan. A 30 × 30 
cm imaging plate (Rigaku R-AXIS VII) detector was placed 1.65 m from the sample 22. 
The wavelength of the incident beam (λ) was 0.10 nm. A bespoke SAXS vacuum 
sample chamber 23 was used and the X-ray transmittance of the samples was determined 
with an ion chamber located in front of the sample and a Si photodiode for X-rays 
(Hamamatsu Photonics S8193) behind the sample. The sample concentration was 1 mM 
in 150 mM NaCl and the exposure time was 300 s for all measurements. The scattering 
intensity 𝐼(𝑞) was measured as a function of the scattering angle of 2𝜃 and 2𝜃 was 
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converted to the magnitude of the scattering vector (𝑞 ) using the equation 𝑞 =(2𝜋 𝜆)sin𝜃. 
2.5.  Cytosolic delivery of ovalbumin-conjugated fluorescein (F-OVA) into RAW264.7 
cells 
RAW264.7 cells were purchased from American Type Culture Collection (Manassas, 
VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan) at 37°C in 5% CO2. F-OVA was dissolved in 
phosphate-buffered saline (PBS). DLPC/DA or EYPC/DA with F-OVA at 5.0 µg/mL 
was added to 2 × 105 cells per six-well plate. After 3 h, the cells were washed twice 
with PBS, stained with Lyso Tracker® Red Lysosomal Probe, in accordance with the 
manufacturer’s protocols, and a cellular image was obtained by confocal microscopy 
(Nikon Co., Tokyo, Japan). 
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V-3 Results and Discussions 
Mixing behavior of DLPC/DA 
Figure 2A shows how the appearance of the solution changed upon the addition of DA 
to DLPC, when the solution’s pH was kept at 7.4 by using MES buffer. DLPC itself did 
not form a stable spherical micelle. According to previous work 24,25, it forms vesicles, 
more precisely multilayered vesicles, and its size can become comparable with the 
visible lights. Therefore, these vesicles in solution exhibit turbidity. Upon adding DA, 
the turbidity decreased and the solution became transparent at  𝜑 = 0.28, where 𝜑 is 
defined by the molar composition ratio of 𝜑 = DA ( DA + DLPC ). This change in 
appearance suggests that the addition of DA decreased the size of aggregates of DLPC 
and DA. This feature is more clearly confirmed by the DLS data shown in Figure 2B, 
where the auto-correlation functions are compared with the different compositions. 
With an increase of 𝜑, the initial slope decreased drastically. By using the software 
supplied by Malvern, 𝑅! was determined, as plotted in Figure 2C. 𝑅! decreased and 
reached to 𝑅! < 10 at 𝜑 = 0.3 and to a plateau at 𝜑 > 0.6. The software was used to 
calculate the polydispersity dispersity index (PDI) for 𝑅! and PDI became smaller 
with an increase of DA. Figure 2C also presents the change in zeta potential, indicating 
that ζ reaches about −30 mV at 𝜑 > 0.62. Its negative charge is due to the carboxylic 
group of the DA acid. At 𝜑 > 0.6, the majority is DA acid and thus we assume that the 
negatively charged carboxylic group covers the surface of the nanoparticle. Hereinafter, 
we set 𝜑 =   0.62 and confirmed that, when the composition was in the range of 𝜑 >   0.6, there were no major differences in the rest of the measurements15. Table 1 
compares the values of 𝑅!, PDI, and ζ. 
Figure 3 illustrates the structural transition that occurred when DA was added to DLPC. 
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DLPC forms multilayered vesicles25, which was confirmed for our system with SAXS, 
showing the typical inter-layer diffraction at 𝑞 = 1.08  and 2.15  nm  (see 
Supplementary Figure 1). Upon adding DA to DLPC, 𝑅! drastically decreased and the 
diffraction peaks disappeared at 𝜑 >   0.5   (data not shown). This means that the 
addition of DA induced the transition from vesicles to spherical micelles. According to 
the packing parameter principle 26, to shift from a vesicle to a spherical micelle, it is 
necessary to increase the volume fraction of the hydrophilic group compared with the 
hydrophobic tail length and volume. Therefore, we assume that the added DA was 
trapped in the hydrophilic domain of the preceding DLPC vesicle and increased the 
domain volume. From the finding that the addition of DA increased the negative ζ value, 
the ionized carboxylic group of DA might have faced the water phase while the steroid 
moiety of DA is located in the hydrophobic core. This ion pairing and the water affinity 
of the carboxylic group were dominant, so the steroid moiety of DA may not have 
become buried deep in the hydrophobic tail domain. Judging from the molecular size, 
the moiety may have been located near the interface. We suppose that the ion pairing 
between the OH group of the DA and the phosphoric group of the DLPC may have 
helped to stabilize the presence of the relatively hydrophobic steroid moiety in the 
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hydrophilic domain. The ionized carboxylic group of DA was confirmed by infrared 
spectroscopy (see the supplementary information). 
pH-responsive membrane disruption 
Figure 4A presents that pH dependence of the pyranine leakage from a giant EYPC 
liposome when DLPC/DA micelles were mixed. The negative controls (each individual 
component): DA, DLPC, and EYPC showed no leakage under all pH conditions. Even 
in the case of EYPC/DA, no leakage was shown. Only when we added a mixture of DA 
and DLPC at 𝜑 = 0.62 was leakage clearly observed at pH < 6. Figure 4B shows the 
pH-leakage plots for other bile acids: chenodeoxycholic (CDA) and ursodeoxycholic 
acids (UDA); as shown by the chemical structures in the figure, the only difference 
between these two compounds is in the chirality of the OH groups at the 3 and 7 
positions, while neither has the position 12 OH. Figure 4B indicates that the 
stereochemistry of the OH groups at the 3 and 7 positions provides a drastic change in 
the pH responsiveness in the leakage, only when mixed with DLPC. Pierrat et al. 
reported that the pKa of ionizable lipids are influenced by coexisting other lipids when 
they are mixed. This pKa shift is caused by lipid-lipid interactions, including that the 
presence of a long hydrophilic spacer between the hydrophobic part of the ionizable 
lipids and the other polar head changes the distance between the heads of the ionizable 
lipids 27. Similarly to this result, the apparent pKa values of CDA and UDA in the 
mixed states may change according to the difference in stereochemistry between CDA 
and UDA. Figure 4C shows the dependence of the pH responsiveness on the alkyl chain 
length (n), where n stands for the carbon number in the phosphatidylcholine lipid family, 
as shown in the figure. When n was greater than 14, no leakage was observed, while at 𝑛 = 10, leakage was observed at both pH 7.4 and 5.0; that is, there was no pH 
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responsiveness. These results suggest that the pH responsiveness of the dual-lipid 
mixtures may have emerged due to the combination of the hydrophobic interaction in 
the alkyl domain and the interactions between the DLPC headgroup and the bile acid, 
created by the position and stereochemical effect of the OH groups in the bile acids.  
Delivery to the cytosol using the DLPC/DA system 
We examined how much F-OVA is transferred into the cytosol upon co-administering 
F-OVA and DLPC/DA to RAW264.7 cells (Figure 5). Lysosomes and late endosomes 
are labeled red by the Lyso Tracker probe 28. After overlaying the red and green (from 
F-OVA) images, DLPC/DA showed a large amount of separation between these two 
colors, while EYPC/DA exhibited an orange color in most areas, meaning that the 
ingested F-OVA was localized at lysosomes. Upon careful examination of the 
distribution of the green color, it appeared to be spread throughout the cell interior, but 
with some still confined to the lysosomes. This experiment demonstrates that DLPC/DA 
provides more cytosolic release of F-OVA than EYPC/DA. This difference corresponds 
to the pH-responsive leakage shown in Figure A. Therefore, we assume that the pH 
responsiveness of DLPC/DA induces the release of F-OVA into the cytosol. 
It should be noticed that there is no interaction between F-OVA (also OVA) and the 
lipids, and they keep free in solution (see the supplementary). Our delivering system is 
designed for vaccination to transfer antigen proteins as well as adjuvants to 
immunocytes. Normally, these vaccines are administrated through subcutaneous or 
intramuscular injection. In these cases, the injected materials tend to stay at the same 
part or be transported to lymphnodes then, eventually engulfed by macrophages or DCs 
29,30. Their local concentrations can be kept relatively high during a certain period and 
there may be a large possibility to be simultaneously ingested. Therefore, it is not 
necessary to bind antigen proteins and pH-responsive particles. 
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Micellar structural changes observed by SAXS 
Figure 6 shows the pH dependence of the SAXS profiles of DLPC/DA. At pH 7.0 and 
6.5, the low q intensity satisfies the relationship 𝐼(𝑞) ∝ 𝑞! with 𝛼 = 0, and there is a 
sharp intensity minimum at 𝑞 = 1.0  nm!!; this value is denoted as 𝑞!!"  !"#. These 
features indicate the formation of spherical micelles from DLPC/DA, with a rather 
narrow size distribution; otherwise, no minimum would be observed. When the 
scattering object is a solid sphere with a radius of R (i.e., a sphere with uniform electron 
density and a sharp interface with the solvent), 𝑅×𝑞!!"  !"#~4.5. This suggests that the 
diameter of the micelle is approximately 9 nm, which is consistent with the DLS result 
in Table 1. We attempted to fit the SAXS profiles at pH 7.0 and 6.5 with a simple model, 
such as a solid sphere or a core-shell double-layer model, but could not obtain a 
reasonable fit. This may have been due to the complex structure of interaction between 
the hydrophilic headgroup of DLPC and DA. 
With an increase of pH, the scaling factor 𝛼  at low q changes from 𝛼 = 0  to 𝛼 = −1.2  to  − 2.0 31. This change can be interpreted in two ways: (i) structural 
transition from sphere to vesicle or plate or (ii) aggregation of preceding spheres. If a 
structural transition takes place, 𝑞!!"  !"! would change, but this is not the case in the 
present system. Therefore, we suppose that the change of 𝛼 is related to aggregation. 
The start of aggregation means that the surface of the micelles becomes less 
water-compatible or hydrophilic. This could be related to protonation of the carboxylic 
group or induced changes between DLPC and DA. Therefore, we can conclude that 
decreasing pH leads to an increase of H+, which increases the population of COOH 
instead of COO−. This directly decreases the hydrophilicity of the micellar surface 
and/or changes the nature of molecular interactions, most likely hydrogen bonding 
between DLPC and DA. This causes secondary aggregation between the micelles. 
  108 
Furthermore, inter-micellar hydrogen bonding can occur through the surface COOH 
groups, which also facilitates the formation of aggregates. 
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Proposing a mechanism of the pH responsiveness of DLPC/DA and its delivery of 
proteins to the cytosol 
When DLPC and DA are mixed at an appropriate ratio, the resultant mixture shows the 
emergent property of pH responsiveness. The pH response range is mainly determined 
by the position and stereochemistry of OH groups in DA and its sensitivity (in terms of 
the leakage test) is related to the hydrophobicity of the alkyl chain of DLPC. The pH 
responsiveness is related to a reduction of hydrophilicity on the micellar surface. Based 
on these results, we can speculate the enhanced efficiency in the protein delivery with 
DLPC/DA system as follows (Figure 7). After DLPC/DA and proteins are ingested by 
endocytosis, the pH of the endosomal vesicle decreases in the late stage. This pH 
change reduces the hydrophilicity of the nanoparticle surface and the particle becomes 
unstable, which leads to aggregation. The endosomal compartment is a spatially 
confined region, and thus the unstable particles may attach to the vesicle bilayers. In 
this process, fusion may occur, leading to the mixing or merging of DLPC and/or DA 
into the bilayers. These events may destabilize the endosomal vesicle and eventually 
lead to its rupture, similar to that leading to leakage of the cargo of giant EYPC vesicles. 
It should be noted that this pH responsiveness only occurs when DLPC and DA are 
mixed.  
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V-4 Conclusions 
The pH responsiveness that emerged for the mixture of DLPC and bile acid is a novel 
and interesting finding. Although the molecular mechanism behind this phenomenon 
has not been completely clarified, the pH response range can be adjusted by changing 
the chemical structure of the bile acid. In terms of safety, both DLPC and bile acids are 
approved as drug materials by the FDA, which reduces the burden in new drug 
development. As our protein delivery assay showed, DLPC/DA can transport 
co-administered materials into the cytosol. This property may be useful for a broad 
range of applications, including antigen-protein delivery32, cancer immunotherapy or for 
therapeutic oligonucleotide delivery, including micro-RNA, siRNA, and antisense 
DNA.  
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V-5 Table and Figures 
Table 1. The diameters and zeta potentials of DLPC and DLPC/DA. 
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Figure 1. Chemical structures of dilauroyl phosphocholine and deoxycholic acid. 
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Figure 2. Composition (𝜑) dependence of the appearance of the DA and DLPC 
mixtures at pH 7.4 (A), and the auto-correlation functions measured with DLS (B), and 
the average hydrodynamic radius and the zeta-potential (C).   
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Figure 3. A schematic illustration of the structural transition from the DLPC vesicle to 
the DLPC/DA spherical micelle; lowering the pH leads to protonation of the carboxylic 
group. DLPC and DA can be represented by a cylinder (or a flat head cone) and a cone, 
respectively, in terms of the packing parameter principle and thus mixing the 
cone-shaped DA to the DLPC bilayer induces a structural transition to spherical shape. 
Decreasing pH leads protonation of the carboxyl group and thus becomes less 
hydrophilic or more favorable to form hydrogen bonds with the DLPC head group. 
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Figure 4. The leakage behavior for the dual-lipid micelles (DLPC/DA in panel A, and 
DLPC/chenodeoxycholic acid and DLPC/ursodeoxycholic acid in panel B) comparing 
their individual components and EYPC/DA, and the effect of the alkyl tail length in 
DLPC analogues on the pH responsiveness, showing that mixing with DLPC and a bile 
acid is necessary to induce pH responsiveness. The tail length dependence of the DLPC 
analogues.  
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Figure 5. Confocal microscopic images upon co-administering only F-OVA and 
F-OVA and DLPC/DA to RAW264.7 cells, compared with those of F-OVA and 
EYPC/DA.  
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Figure 6. The pH dependence of SAXS profiles of DLPC/DA.  
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Figure 7. A schematic illustration of the protein delivery with the DLPC/DA system, 
when they are co-administrated (see the text in detail).
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Supplementary Figure 
 
Supplementary Figure 1. Typical inter-layer diffraction of DLPC (black) and 
DLPC/DA (gray)  
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Supplementary Figure 2. The mixture of F-OVA and DLPC/DA. The fluoresense of 
F-OVA was observed after migration at 30 min to 12 wt % acrilamidegel 
electrophoresis.  
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Chapter VI 
Summary and Conclusions  
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In this thesis we have explored the drug delivery system of CpG-ODN into SPG for 
cancer vaccine, cytosol delivery with cell penetrating peptide into SPG, and 
characterization of pH responsiveness micelle. The following summarized the results 
obtained in each chapter. 
Preparation and characterization of crosslinking(CL)-CpG complex (Chapter II) 
β-Glucan schizophyllan (SPG) and CpG-dA40 can form a complex (CpG-dA40/SPG), 
which drastically induces immune-response owing to a combination of 
immunocyte-targeting delivery due to SPG and immunostimulative CpG ODN. We 
made a crosslinked larger particle than the original one by using hybridization. The 
crosslink particles showed higher immune stimulation and can thus be used as a more 
potent vaccine adjuvant than CpG-dA40/SPG itself. 
Approach as a Cancer vaccination with CL-CpG (Chapter III) 
Cancer vaccine has an ability to directly eradicate tumor cells by creating and activating 
cytotoxic T lymphocytes (CTLs). To achieve efficient CTL activity and to induce Th1 
responses, it is essential to administer an appropriate adjuvant as well as an antigen. 
CpG-ODN is known as a ligand of Toll-like receptor 9 (TLR9) and strongly induces 
Th1 responses. In our previous study, we developed a CpG-ODN delivery system by 
use of the formation of complexes between ODN and a beta-glucan SPG, denoted 
CpG/SPG, and demonstrated that CpG/SPG induces high Th1 responses. In this study, 
we created a nanogel made from CpG/SPG complexes through DNA-DNA 
hybridization [crosslinked (CL)-CpG]. Immunization with CL-CpG induced much 
stronger antigen-specific Th1 responses in combination with the antigenic protein 
ovalbumin (OVA) than that with CpG/SPG. Mice pre-immunized with CL-CpG and 
OVA exhibited a long delay in tumor growth and an improved survival rate after tumor 
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inoculation. These immune inductions can be attributed to the improvement of cellular 
uptake by the combination of increased size and the cluster effect of the beta-glucan 
recognition site in the nanogel structure. In other words, the particle nature of CL-CpG, 
instead of the semiflexible rod conformation of CpG/SPG, enhanced the efficacy of a 
cancer vaccine. The present results indicate that CL-CpG can be used as a potent 
vaccine adjuvant for the treatment of cancers and infectious diseases. 
Cytosol delivery by using cell penetrating peptide with SPG (Chapter IV) 
Antisense-oligonucleotides (AS-ODNs) are not able to protect the bound ODN against 
degradation enzyme in biological fluids and be taken up by targeting cells. To solve 
these issues, the development of drug delivery systems to deliver AS-ODNs has been 
studied. 
We have studied a polysaccharide schizophyllan (denoted by SPG), a member of 
β-glucans, as a delivery carrier of oligonucleotides. SPG can form a complex with 
polydeoxyadenosine (denoted by dA base numbers) and prevents degradation by 
enzymes. We have reported that the complex comprising of SPG and the dA40 that was 
beforehand connected with AS-ODNs (AS-ODN-dA40). The complex can deliver 
AS-ODNs to dectin-1-expresseing cell and silence mRNA, then, eventually suppress 
protein expressions.  
TAT peptide: human immunodeficiency virus type 1 protein fragments is known one of 
the major arginine-rich cell penetrating peptides. We prepared TAT peptide conjugate 
phosphorothioate dA40 oligonucleotide (denoted by TAT-dA40) by the click chemistry 
reaction. The TAT-dA40/ASHER3/SPG complexes showed a higher cell uptake and 
more cell-growth suppression than AS-yb-1-dA40/SPG complex that had not TAT. We 
suppose that this improvement can be ascribed to TAT-induced cellular ingestion of the 
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complexes. 
pH responsiveness carrier and cytosol delivery(Chapter V) 
Providing appropriate pH responsiveness for drug delivery nanoparticles is one of the 
major issues in developing a new generation of delivery systems. This paper reports that, 
when phosphocholine and a bile acid were mixed, the resultant two-component micelle 
gained pH responsiveness, while the individual components did not show any such 
responsiveness. The pH responsiveness was shown to be determined by the chemical 
structure, especially the positions and chirality of the OH groups, of the bile acid, and 
the sensitivity was determined by the alkyl chain length of the phosphocholine. The best 
combination for evading endocytosis was dilauroyl phosphocholine (DLPC) and 
deoxycholic acid (DA). Small-angle X-ray scattering revealed that the pH 
responsiveness was related to the change of surface hydrophobicity, namely, decreasing 
pH led to protonation of the carboxylic acid, resulting in aggregation of the preceding 
micelles. We assume that particles that become hydrophobic in this way can start 
interacting with the endocytotic bilayer, which eventually leads to rupture of the 
endocytotic vesicle. This mechanism is well supported by the finding that 
fluorescein-conjugated ovalbumin proteins were transported into the cytosol when they 
were co-administered with DLPC/DA. 
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Chapter VII 
The Philosophy of This Research 
Research is a creature and changes with the times. 
The mature it teaches and gives me all things. Occasionally it teaches life and to touch a 
lot of contribution and knowledge of many giant. On the other hand, the immature it 
gives me curiousness and to research opportunity. 
I would like to take part world medical as a researcher at long time. And I would like to 
be a researcher to form my curious and interesting. 
In this Ph.D. student era, I thought such an above. 
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